Coverage Policies

Use the index below to search for coverage information on specific medical conditions.

Note: For Arkansas State or Public School employees, services subject to pre-authorization are managed by Active Health Management, as noted in their Summary Plan Description.

For coverage information on high tech imaging (MRI, CT, PET) and nuclear medicine, administered by Evicore, click here.

Medical Providers: Payment for care or services is based on eligibility, medical necessity and available benefits at time of service and is subject to all contractual exclusions and limitations, including pre-existing conditions if applicable.

Future eligibility cannot be guaranteed and should be rechecked at time of service. Verify benefits by signing into My Account or calling Customer Service at 800.235.7111 or 501.228.7111.

If not specified in a QualChoice coverage policy (Benefit Interpretation), QualChoice follows care guidelines published by MCG Health.

QualChoice reserves the right to alter, amend, change or supplement medical policies as needed. QualChoice reviews and authorizes services and substances. CPT and HCPCS codes are listed as a convenience and any absent, new or changed codes do not alter the intent of the policy.


Effective Date: 04/01/2015 Title: Lynparza (Olaparib)
Revision Date: 01/01/2019 Document: BI479:00
CPT Code(s):
Public Statement

Effective Date:

a)    This policy will apply to all services performed on or after the above revision date which will become the new effective date.

b)    For all services referred to in this policy that were performed before the revision date, contact customer service for the rules that would apply.

1)    Lynparza (Olaparib) requires prior authorization.

2)  Lynparza is used to treat a type of advanced ovarian cancer and invasive breast cancer.

Medical Statement

Lynparza (Olaparib) is considered medically necessary for patients with advanced ovarian cancer and ALL of the following:

1)    BRCA-positive mutation  AND

2)    Prior therapy with 3 or more lines of chemotherapy  AND

3)    NO concurrent therapy with other agents for the treatment of ovarian cancer.


Lynparza is considered medically necessary for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in a complete or partial response to platinum-based chemotherapy, as monotherapy.


Lynparza (Olaparib) is considered medically necessary for patients with invasive breast cancer with the following characteristics:

1) HER-2 negative AND

2) BRCA-positive mutation AND

3) Prior therapy with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting AND

4) If HR-positive must have either:

a.    Previous treatment with endocrine therapy OR

b.    Considererd an inappropriate candidate therapy for endocrine therapy.


As a specialty medication, Lynparza is limited to no more than a 30 day supply per fill.


1)    Lynparza Prescribing Information.  Astra Zeneca.  August 2017.

2)    NCCN Compendium.  Accessed online 5/14/2018.

3)    Clinical Pharmacology.  Accessed online 5/14/2018.

Application to Products
This policy applies to all health plans administered by QualChoice, both those insured by QualChoice and those that are self-funded by the sponsoring employer, unless there is indication in this policy otherwise or a stated exclusion in your medical plan booklet. Consult the individual plan sponsor Summary Plan Description (SPD) for self-insured plans or the specific Evidence of Coverage (EOC) for those plans insured by QualChoice. In the event of a discrepancy between this policy and a self-insured customer’s SPD or the specific QualChoice EOC, the SPD or EOC, as applicable, will prevail. State and federal mandates will be followed as they apply.
Changes: QualChoice reserves the right to alter, amend, change or supplement benefit interpretations as needed.
This policy has recently been updated. Please use the index above or enter policy title in search bar for the latest version.